Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 851 to 860 of 1090 total matches.
Intravenous Diclofenac (Dyloject)
The Medical Letter on Drugs and Therapeutics • Dec 21, 2015 (Issue 1484)
with moderate to severe
hepatic impairment.
DRUG INTERACTIONS — Diclofenac is metabolized
primarily by CYP2C9 ...
The FDA has approved Dyloject (Hospira), an IV
formulation of the NSAID diclofenac sodium, for use
in adults. It can be administered alone for treatment
of mild to moderate pain or in combination with opioid
analgesics for moderate to severe pain. Dyloject is the
first injectable formulation of diclofenac to become
available in the US.
Seebri Neohaler and Utibron Neohaler for COPD
The Medical Letter on Drugs and Therapeutics • Mar 28, 2016 (Issue 1491)
contractility during labor.
DRUG INTERACTIONS — The hypokalemic effects of
indacaterol may be potentiated ...
The FDA has approved two new inhalers for long-term
maintenance treatment of chronic obstructive
pulmonary disease (COPD). Seebri Neohaler
(Novartis) contains the long-acting anticholinergic
glycopyrrolate. Utibron Neohaler (Novartis) contains
both glycopyrrolate and the long-acting beta2-adrenergic agonist (LABA) indacaterol. Glycopyrrolate/indacaterol is the third fixed-dose combination of a
long-acting anticholinergic and a LABA to become
available in the US; umeclidinium/vilanterol (Anoro
Ellipta) and tiotropium/olodaterol (Stiolto Respimat)
were approved...
Sublingual Apomorphine (Kynmobi) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020 (Issue 1609)
, hallucinations,
and psychosis.
DRUG INTERACTIONS — Use of sublingual apomorphine
with 5-HT3 receptor ...
The FDA has approved a sublingual fi lm formulation
of the nonergot dopamine agonist apomorphine
(Kynmobi – Sunovion) for acute, intermittent treatment
of "off" episodes in patients with Parkinson's disease
(PD). A subcutaneous formulation of apomorphine
(Apokyn) has been available for years for the same
indication in patients with advanced PD.
Azstarys (Serdexmethylphenidate/Dexmethylphenidate) for ADHD
The Medical Letter on Drugs and Therapeutics • Oct 04, 2021 (Issue 1634)
milk; the drug is generally considered
safe for breastfeeding women.5
DRUG INTERACTIONS — Concurrent ...
The FDA has approved a long-acting fixed-dose
combination of the stimulant dexmethylphenidate
and the prodrug serdexmethylphenidate (Azstarys –
Corium) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years
old. Azstarys is the first product containing serdexmethylphenidate
to become available in the US.
Asenapine (Saphris) Sublingual Tablets for Schizophrenia and Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Feb 08, 2010 (Issue 1331)
INTERACTIONS — Asenapine serum concentrations may increase when the drug is taken with a
strong inhibitor ...
Asenapine (Saphris - Schering-Plough), a dibenzo-oxepino pyrrole, has been approved by the FDA in a sublingual tablet formulation for acute treatment of schizophrenia and manic or mixed episodes associated with bipolar disorder. It is the sixth second-generation antipsychotic approved by the FDA for use in bipolar disorder.
Fentanyl Buccal Soluble Film (Onsolis) for Breakthrough Cancer Pain
The Medical Letter on Drugs and Therapeutics • Apr 19, 2010 (Issue 1336)
Issue 1336 April 19, 2010
DRUG INTERACTIONS — Co-administration with
CYP3A4 inhibitors ...
Fentanyl buccal soluble film (Onsolis – Meda) has been approved by the FDA for treatment of breakthrough pain in adult cancer patients who are already taking and are tolerant to around-the-clock opioid therapy. It is designated as a Schedule II controlled substance Two other oral transmucosal formulations of fentanyl are already available for this indication.
Tocilizumab (Actemra) for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Jun 14, 2010 (Issue 1340)
arthritis and contributes to
joint destruction.
DRUG INTERACTIONS — In vitro data indicate ...
The FDA has approved tocilizumab (Actemra – Genentech; RoActemra in Europe) for intravenous
(IV) treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an
inadequate response to tumor necrosis factor (TNF) inhibitors.
Atomoxetine (Strattera) for ADHD
The Medical Letter on Drugs and Therapeutics • Feb 03, 2003 (Issue 1149)
. Patients with moderate hepatic dysfunction should take half the usual dose.
DRUG INTERACTIONS — Monoamine ...
Atomoxetine (Strattera - Lilly) is the first non-stimulant drug to be approved by the FDA for treatment of attention deficit hyperactivity disorder (ADHD). Unlike other drugs approved for use in ADHD, it is not a controlled substance and is approved for use in adults as well as children. Older non-stimulant drugs that have been used to treat ADHD, although not FDA-approved, include the alpha2-agonist clonidine (Catapres, and others) and the tricyclic antidepressant desipramine (Norpramin, and others) (Medical Letter 1996; 38:109).
BiDil for Heart Failure
The Medical Letter on Drugs and Therapeutics • Sep 28, 2005 (Issue 1218)
Letter
®
On Drugs and Therapeutics
IN THIS ISSUE
Volume 47 (Issue 1218)
September 26, 2005 ...
BiDil (NitroMed), a fixed-dose combination of isosorbide dinitrate and hydralazine, was approved by the FDA for adjunctive use in the treatment of heart failure in black patients.Both drugs are oral vasodilators that have been used together off-label for many years to treat heart failure in patients not responding to other drugs.
Bevacizumab (Avastin) for Metastatic Breast Cancer
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008 (Issue 1287)
Letter
®
On Drugs and Therapeutics
Volume 50 (Issue 1287)
June 2, 2008
www.medicalletter.org ...
Bevacizumab (Avastin - Genentech) is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor and prevents it from binding to receptors on endothelial cells, inhibiting formation of new blood vessels. Previously approved by the FDA for use in combination regimens for first-line treatment of metastatic colon cancer and metastatic non-small cell lung cancer, and used off-label for treatment of agerelated macular degeneration, it has now also been approved by the FDA for use in combination with paclitaxel (Taxol, and others) for first-line treatment of...